Side effects not a major problem for new class of breast cancer drugs

(Wiley) A ground-breaking new class of oral drugs for treating breast cancer, known as cyclin-dependent kinase (CDK) inhibitors, are generally well-tolerated, with a manageable toxicity profile for most patients.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news